Shares of Trinity Biotech (NASDAQ:TRIB) traded sharply higher on Tuesday after the Irish MedTech reported encouraging data from a pre-pivotal clinical trial for its next-gen continuous glucose ...

(Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system.

Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management.

DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions ...

Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), an Ireland-based biotech firm with a market capitalization of $13.24 million, revealed promising results from a recent pre-pivotal clinical trial for ...